Business Trends 2008 Understanding Your BPO Customer (Customer Focus)

Analysis of major trends within the BPO market, using end user sentiment from 150 respondents in eight countries.

Report Highlights
Business process outsourcing has matured rapidly in recent years. Once seen simply as a means to cut costs, it is now also viewed by many end users as a tool for increasing efficiency and enhancing performance.

Datamonitor's 2008 BPO Business Trends survey gathers the opinions of companies currently engaged in BPO contracts. It looks at trends across the three main horizontal areas of BPO: human resources outsourcing, finance and accounting outsourcing and procurement outsourcing.
[Studien Infos ausblenden]

Table 1: Definition of the cancer market, 2008 8
Table 2: Seven major market sales of antihormonal therapy cancer brands by drug class, 2007 11
Table 3: Seven major market sales of antihormonal therapy cancer brands, 2007 14
Table 4: Individual country sales of antihormonal therapy cancer brands, 2007 16
Table 5: Seven major market forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 18
Table 6: Seven major market forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 21
Table 7: Individual country forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 24
Table 8: US sales of antihormonal therapy cancer brands by drug class, 2007 28
Table 9: US sales of antihormonal therapy cancer brands, 2007 30
Table 10: US forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 31
Table 11: US forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 34
Table 12: Japan sales of antihormonal therapy cancer brands by drug class, 2007 36
Table 13: Japan sales of antihormonal therapy cancer brands, 2007 38
Table 14: Japan forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017 39
Table 15: Japan forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 42
Table 16: 5EU sales of antihormonal therapy cancer brands by drug class, 2007 44
Table 17: 5EU major market sales of antihormonal therapy cancer brands, 2007 46
Table 18: 5EU forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 47
Table 19: 5EU forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 50
Table 20: France sales of antihormonal therapy cancer brands by drug class, 2007 52
Table 21: France sales of antihormonal therapy cancer brands, 2007 54
Table 22: France forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 55
Table 23: France forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 58
Table 24: Germany sales of antihormonal therapy cancer brands by drug class, 2007 60
Table 25: Germany sales of antihormonal therapy cancer brands, 2007 62
Table 26: Germany forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 63
Table 27: Germany forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 66
Table 28: Italy sales of antihormonal therapy cancer brands by drug class, 2007 68
Table 29: Italy sales of antihormonal therapy cancer brands, 2007 70
Table 30: Italy forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 71
Table 31: Italy forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 74
Table 32: Spain sales of antihormonal therapy cancer brands by drug class, 2007 76
Table 33: Spain sales of antihormonal therapy cancer brands, 2007 78
Table 34: Spain forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 79
Table 35: Spain forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 82
Table 36: UK sales of antihormonal therapy cancer brands by drug class, 2007 84
Table 37: UK sales of antihormonal therapy cancer brands, 2007 86
Table 38: UK forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017 87
Table 39: UK forecast sales of antihormonal therapy cancer brands ($m), 2007-2017 90
Table 40: US, Japan, 5EU and RoW total antihormonal therapy market sales, 2007 92
Table 41: US, Japan, 5EU and RoW total LHRH analog therapy market sales, 2007 94
Table 42: US, Japan, 5EU and RoW total anti-estrogen therapy market sales, 2007 96
Table 43: US, Japan, 5EU and RoW total anti-androgen therapy market sales, 2007 98
Table 44: US, Japan, 5EU and RoW total aromatase inhibitors therapy market sales, 2007 100
Table 45: CAGR (%) of antihormonal therapy cancer brands by drug class, 2007-2017 109
Table 46: CAGR (%) of antihormonal therapy cancer brands, 2007-2017 111
Table 47: Afema: key facts 128
Table 48: Afema forecast sales in the seven major markets ($m), 2007-2017 129
Table 49: Arimidex: key facts 130
Table 50: Arimidex: brand forecast events 131
Table 51: Arimidex forecast sales in the seven major markets ($m), 2007-2017 132
Table 52: Aromasin: key facts 134
Table 53: Aromasin: brand forecast events 135
Table 54: Aromasin forecast sales in the seven major markets ($m), 2007-2017 136
Table 55: Casodex: key facts 138
Table 56: Casodex: brand forecast events 139
Table 57: Casodex forecast sales in the seven major markets ($m), 2007-2017 140
Table 58: Fareston: key facts 141
Table 59: Fareston: brand forecast events 142
Table 60: Fareston forecast sales in the seven major markets ($m), 2007-2017 143
Table 61: Faslodex: key facts 144
Table 62: Faslodex: brand forecast events 145
Table 63: Faslodex forecast sales in the seven major markets ($m), 2007-2017 146
Table 64: Femara: key facts 147
Table 65: Femara: brand forecast events 148
Table 66: Femara forecast sales in the seven major markets ($m), 2007-2017 149
Table 67: Lupron: key facts 151
Table 68: Lupron forecast sales in the seven major markets ($m), 2007-2017 152
Table 69: Nolvadex: key facts 154
Table 70: Nolvadex forecast sales in the seven major markets ($m), 2007-2017 155
Table 71: Suprefact: key facts 157
Table 72: Suprefact forecast sales in the seven major markets ($m), 2007-2017 158
Table 73: Zoladex: key facts 159
Table 74: Zoladex forecast sales in the seven major markets ($m), 2007-2017 160
Table 75: Abbreviations used in DMHC2415 Antihormonal Therapy Cancer Brands 168

[Tabellenverzeichnis ausblenden]